<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642601</url>
  </required_header>
  <id_info>
    <org_study_id>MS62014</org_study_id>
    <nct_id>NCT02642601</nct_id>
  </id_info>
  <brief_title>Role of Indomethacin in Difficult Embryo Transfer.</brief_title>
  <official_title>Role of Indomethacin in Cases of Difficult Embryo Transfer in Intra Cytoplasmic Sperm Injection Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of the study is to assess the role of indomethacin in cases of difficult embryo
      transfer in intracytoplasmic sperm injection cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective randomized study in which 200 women undergoing ICSI( intracytoplasmic
      sperm injection) and fulfilling the inclusion criteria(Difficult mock embryo transfer on day
      of ovum pick up ,Women's age 20-38 yaears,Early follicular FSH ≤10 IU/l ,Tubal, male
      infertility, unexplained factors of infertility.) will be recruited.

      All patients will received long stimulation protocol ;down regulation will be achieved by
      administration of triptorelin0.1 mg(decapeptyl 0.1 mg, Ferring, Malmo, sweden) S.C daily from
      day 21 of the cycle preceding the stimulation cycle till the day of hCG administration.,down
      regulation will be checked day 2 of stimulation cycle by checking serum E2˂50 pg/ml,
      endometrial thickness ˂ 5mm and quiescent both ovaries.

      When down regulation is achieved stimulation is commenced using hmG(Menogon, ferring
      pharmaceuticals, Germany) 225 IU daily intramuscular injection, Serial trans-vaginal
      ultrasound to assess follicular growth and serum E2 are done starting on day 6 of the cycle
      and onward, with adjustments of gonadotropin dose and monitoring frequency based on patient
      response.

      Once 3 or more leading follicles reached≥18mm hCG 10000 IU (Pregnyl; NV Organon) will be
      administrated IM.

      Ovum pick up will be done 34-36 hours following hCG administration with ultrasound guidance
      under general anesthesia.after that mock embryo transfer will be done using labotec embryo
      transfer catheter and women in which any degree of difficulty according to Tomas et al. 2002
      criteria will be recruited in the study and divided randomly into two groups according to
      computer generated random cards ;group A (n=100): will receive indomethacin 100 mg rectal
      supp(KAHIRA PHARMA&amp;CHEM,IND,CO.CAIRO-EGYPT) 1-2 hours before embryo transfer, group B (n=100)
      will not receive any medications before embryo transfer.

      Embryo transfer of 2 embryos will be done by the same technique in lithotomy position with
      full bladder under ultrasound guidance 2-3 days after ovum pick up depending on the number
      and quality of available embryos using labotec catheter (Labotec, Gottingen Germanny).

      Luteal phase will be achieved Using progesterone vaginal pessaries (Cyclogest, Alpharma, UK)
      400 mg twice daily from the day of egg collection till the day of the pregnancy test and
      continued till 12 week gestation if pregnancy is documented.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>2 weeks after +ve pregnancy test</time_frame>
    <description>+ve pregnancy test+ gestational sac with fetal pulsation by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>the number of total gestational sacs divided by the total number of embryos transferred.</time_frame>
    <description>2-4 weeks after positive pregnancy test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>after 12 weeks gestation</time_frame>
    <description>pregnancy exceeding 12 weeks gestation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Difficult Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>indomethacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one dose of indomethacin 100 mg rectal suppository;will be adminstrated1-2 hours before embryo transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no indomethacine before embryo transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin(KAHIRA PHARMA&amp;CHEM,IND,CO.CAIRO-EGYPT)</intervention_name>
    <description>one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer</description>
    <arm_group_label>indomethacin</arm_group_label>
    <other_name>indocid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infertile patients undergoing ICSI cycle with difficult mock transfer done on day of
             day of ovum pick up

        Exclusion Criteria:

          -  repeated ICSI failure

          -  Easy mock embryo transfer on day of ovum pick up

          -  Early follicular FSH &gt;10 IU/l

          -  Past history of allergy to NSAID.

          -  Past history of asthma, peptic ulcer disease or inflammatory bowel disease.
             Endometrial pathology
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona M Shaban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mona M Shaban, MD</last_name>
    <phone>+201001078586</phone>
    <email>drmonashaban@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherin H Gad Allah, MD</last_name>
    <phone>+201097665573</phone>
    <email>sherinehosny@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVF center,Cairo university hospital,Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherin H Gad Allah, MD</last_name>
      <phone>+201097665573</phone>
      <email>sherinehosny@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mona M Shaban, MD</last_name>
      <phone>+201001078586</phone>
      <email>drmonashaban@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kamal Shoeir private IVF center,Cairo,Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona M Shaban, MD</last_name>
      <phone>+201001078586</phone>
      <email>drmonashaban@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sherine H Gad Allah, MD</last_name>
      <phone>+201097665573</phone>
      <email>sherinehosny@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>December 24, 2015</last_update_submitted>
  <last_update_submitted_qc>December 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mona M Shaban</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>indomethacin, ICSI, difficult embryo transfer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 2, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>April 11, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>April 15, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

